61 results
Keyword Zostavax Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Zostavax
varicella-zoster virus (live, attenuated), Herpes Zoster; Immunization
Date of authorisation: 19/05/2006, Revision: 33, Authorised, Last updated: 01/07/2022Zostavax Varicella Zoster Virus Infection Herpesviridae … Zostavax … Zostavax: Product Information as approved … -
List item
Referral: Monovalent and multivalent measles, mumps, rubella and / or varicella vaccines
monovalent and multivalent measles, mumps, rubella and varicella vaccines (live), associated names: Amunovax, Priorix, Priorix Tetra, Provarivax, R.O.R. Vax, Rouvax, Trivivac, Varilrix, Varivax, Article 31 referrals
Status: European Commission final decision, opinion/position date: 13/12/2012, EC decision date: 27/06/2013, Last updated: 12/03/2014zoster (shingles) vaccine Zostavax, are centrally authorised … risk. (This does not apply to Zostavax, which has different strength … Commission issued a decision for Zostavax Article 20 on 13 February … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Copalia, varicella-zoster virus (live, attenuated)
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Vaccines
PIP number: EMEA-001672-PIP01-14, Route(s) of administration: Subcutaneous use, Intramuscular use, Pharmaceutical form(s): Powder and solvent for suspension for injection
Decision date: 24/11/2014, Last updated: 12/12/2014, Compliance check: XInvented name Copalia Zostavax Active substance varicella-zoster … EMEA-001672-PIP01-14). What is Zostavax (varicella-zoster virus (live … is it expected to work? Zostavax (varicella-zoster virus (live … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2012
CHMP, Last updated: 14/12/2012M-M-RVAXPRO, ProQuad, Zostavax, Amunovax, Priorix, Priorix … -
List item
Press release: European Medicines Agency: Committee for Medicinal Products for Human Use 20-23 March 2006
CHMP, Last updated: 24/03/2006Zostavax … review time of 196 days. § Zostavax (herpes zoster vaccine … vaccine), Sanofi Pasteur MSD. Zostavax is a vaccine intended for … -
List item
Human medicine European public assessment report (EPAR): Shingrix
Recombinant varicella zoster virus glycoprotein E, Herpes Zoster
Date of authorisation: 21/03/2018, Revision: 9, Authorised, Last updated: 19/12/2022 -
List item
News: European Immunization Week 2022: Statement by Executive Director Emer Cooke - Why vaccines contribute to a “Long Life for All”
Last updated: 25/04/2022(29/05/2020) Ervebo Shingrix Zostavax … -
List item
Human medicine European public assessment report (EPAR): Rinvoq
upadacitinib, Arthritis, Rheumatoid
Date of authorisation: 16/12/2019,
, 
, Revision: 13, Authorised, Last updated: 13/12/2022
-
List item
Human medicine European public assessment report (EPAR): Xeljanz
Tofacitinib, Arthritis, Rheumatoid
Date of authorisation: 22/03/2017,
Date of refusal: 25/04/2013,, Revision: 26, Authorised, Last updated: 04/10/2022
-
List item
Referral: Janus kinase inhibitors (JAKi) (updated)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/03/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 25-28 October 2021
European Medicines Agency, Amsterdam, the Netherlands, from 25/10/2021 to 28/10/2021, Last updated: 02/08/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 April 2021
European Medicines Agency, Amsterdam, the Netherlands, from 19/04/2021 to 22/04/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 February 2021
European Medicines Agency, Amsterdam, the Netherlands, from 22/02/2021 to 25/02/2021, Last updated: 07/12/2021 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 17/03/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 21/06/2021 to 24/06/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 18-21 May 2015
European Medicines Agency, London, UK, from 18/05/2015 to 21/05/2015, Last updated: 03/01/2014 -
List item
CHMP: Agendas, minutes and highlights
Last updated: 08/02/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 10-13 June 2014
European Medicines Agency, London, UK, from 10/06/2014 to 13/06/2014, Last updated: 13/08/2013 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 September 2018
European Medicines Agency, London, UK, from 17/09/2018 to 20/09/2018, Last updated: 31/10/2018 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 30 November-3 December 2015
European Medicines Agency, London, UK, from 30/11/2015 to 03/12/2015, Last updated: 13/03/2014 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 October 2015
European Medicines Agency, London, UK, from 19/10/2015 to 22/10/2015, Last updated: 03/01/2014 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 November 2014
European Medicines Agency, London, UK, from 03/11/2014 to 06/11/2014, Last updated: 13/08/2013 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 December 2013
European Medicines Agency, London, UK, from 02/12/2013 to 05/12/2013, Last updated: 02/07/2012 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 13-16 May 2013
European Medicines Agency, London, UK, from 13/05/2013 to 16/05/2013, Last updated: 02/07/2012 -
List item
Committee for Medicinal Products for Human Use (CHMP): 8-11 November 2021
Online, from 08/11/2021 to 11/11/2021, Last updated: 20/01/2022